NCT04810728View on ClinicalTrials.gov

Efficacy of Psidii Guava's Extract For COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

December 4, 2020

Study Completion Date

January 30, 2021

Conditions
Covid19
Interventions
DRUG

Extract Psidii guava

2 Capsule Extract Psidii guava, three times daily

COMBINATION_PRODUCT

Standard therapy for Covid-19 patient

(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)

Trial Locations (1)

25586

Faculty of Medicine, Baiturrahmah University, Padang

All Listed Sponsors
lead

Faculty of Medicine Baiturrahmah University

OTHER

NCT04810728 - Efficacy of Psidii Guava's Extract For COVID-19 | Biotech Hunter | Biotech Hunter